礼来公司旗下药物Selpercatinib的总体生存数据在初步分析中显示出积极倾向,但由于观察期内事件发生数量较少,当前研究结果尚未达到成熟阶段。
礼来公司旗下药物Selpercatinib的总体生存数据在初步分析中显示出积极倾向,但由于观察期内事件发生数量较少,当前研究结果尚未达到成熟阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.